Clay Siegall’s Devotion on Biotechnology

Clay Siegall is the president, co-founder, and CEO of Seattle Genetic. He is a very successful man who has beaten all odds to be where he is. Clay is also a philanthropist who has done so much for the community. He has a Ph.D. in genetics from George Washington University as well as a B.S from the University of Maryland in Zoology. He is an accomplished scientist and entrepreneur. Since he is a scientist, Clay Siegall is driven to the world of biotechnology. His dedication to his work made him get an award in computer, math and natural sciences of the Alumnus of 2013 from Maryland University.

Biotechnology is defined as the gathering of specific microorganisms for the purpose of inventing medicine by manufacturing these microorganisms. Before the end result, these microorganisms are well checked by the scientists to come up with the best treatment for cancer. Seattle Genetics has joined hands with other companies to establish the best antibody drug conjugate (ADC). On the other hand, the victims of different forms of cancer are hopeful that the company will find the best therapy to help them move on with their life. This collaboration has succeeded in initiating the first medicine which is Adcetric and as a result, it has been distributed to more than 60 countries.

The success of Seattle Genetics includes their earning get higher thus their financial graph becoming even better. This firm has been able to deliver over 20 ADCs to clinics. The organization has made $330 million since it was started and this shows how hard they have been working. Furthermore, the patients are receiving so much care from the firm.

Other than Adcetric the company has also come up with SGN-CD33A. there is a cancer form called acute myeloid which have received this medicine. As a result, this drug is working well and the patients are getting better each day. The company is working on creating excellent cancer therapies that will overcome the disease cancer. Moreover, Seattle Genetics has associated with similar companies for a common goal of establishing better therapies that will help cancer patients.